Meet The Team
Founder & CEO
Lynnet Koh, MBA
Lynnet Koh has extensive executive experience in leading major new technology and product innovations including new product design, development, and commercialization of multiple cutting-edge technologies within the telecom and biotecnology industries.
Chief Business Officer
John Leonard, MBA
John Leonard has more than 20 years of biopharma expereince focused on strategy, financing, and corporate dealmaking. He has led multi-billion dollar licensing and M&A deals in Cell and Gene therapy at Thermo Fisher. John has served in science and business leadership roles at Eli Lilly, Genzyme, GSK, CASI Pharmaceuticals, HUYABIO International and CereGene.
Chief Medical Officer, Chair of Medical Board
Paul Grint, MD
Dr. Paul Grint was most recently CEO and a member of the board of directors of AmpliPhi Biosciences which recently merged with C3J Therapeutics to form Armata Pharmaceuticals. Dr. Grint has more than two decades of experience in biologics including the successful approval and commercialization of products infectious diseases, immunology and oncology.
Chief Patent Strategist
David Kyle, PhD
David Kyle is a serial biotech entrepreneur with 40 years of expereince. Dr. Kyle has founded multiple companies to exits including Martek Biosciences, Advanced BioNutrition, and Evolve BioSystems. (now Infinant Health)
Vice President of Oncology R&D
Reid Bissonnette, PhD
Dr. Bissonnette is TargaZyme’s Head of oncology drug discovery and senior manager with more than 25-years-experience from discovery to commercialization.
VP of Medical Affairs and Physician Scientist
Ashok Srivastava, MD, PhD, MBA
Improving the lives of patients by treating them directly and researching potential new therapies, cures and preventative medicine options.
Vice President of CMC and Head of Operations
Dr He is a Bioprocess Development and Manufacturing professional with extensive leadership experience in managing cross functional teams and leading multiple programs and projects simultaneously in Biopharmaceutical industry. Previously served as CTO at Legend Biotech and helped lead the company to an 8 billion dollar market cap.
Chair of Regulatory Affairs
James Manuso, PhD
Dr. James S. Manuso is a biopharmaceutical industry CEO and serial entrepreneur experienced in the foundation, management, financing, governance and more than 2 billion dollar M&A of a start-up. Dr. Manuso serves as a director on the boards of Ocuphire (NASDAQ: OCUP) and Morphogenesis, Inc.
Emeritus SVP of Regulatory Affairs
Audrey Jakubowski, PhD
Dr. Jakubowski started her career at Bristol Myers, where she built and led a regulatory group that focused on building a single, international dossier that could be submitted around the globe. Dr. Jakubowski has submitted multiple New Drug Applications, both in the U. S. and abroad. She also served as FDA advisor and elected member of the PhRMA Regulatory Affairs Committee.
Lead Bio-Statitian
Sin Ho Jung, MD, PhD
Dr Jung is professor of Biostatistics & Bioinformatics at Duke University, member of the Duke Cancer Institute, and Division of Integrative Genomics.
Chair of CMC Committee
Richard Martin, MD
Dr. Martin is an accomplished pharmaceutical executive with over 20 years of R&D experience in the fields of antibacterial, inflammation, oncology, antiviral, antifungal, cardiovascular and metabolic diseases, and glycosciences.
Medical Consultant
Dennis Kim, MD
Harvard MD, Dr. Kim helps assists Targazyme with clinical trial protocol writing. He curretnly serves as Chief Medical Officer at Panthera Life Sciences and has previously led Medical Affiairs programs at Ipsen, Spectrum Pharma and Novartis.